Pharma BD Deal Intelligence
OBI Pharma entered a collaboration and license agreement with Novartis Pharma AG to develop next-generation antibody-drug conjugates using OBI's platform technologies (GlycOBI, EndoSymeOBI, HYPrOBI and GlycOBI DUO). Novartis receives worldwide exclusive rights to OBI's related patents and know-how for selected, undisclosed Novartis payload classes. OBI receives USD 30 million upfront and is eligible for development, regulatory and commercial milestones taking total potential deal value above USD 2 billion, plus tiered royalties on net sales.
← Browse all deals · How we score deals
More: 2026 deals · Novartis AG deals